US 9,446,062 B2 · Methods of treating ischemia-reperfusion injury with siRNAs

Abstract

The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject. The invention also provides antibodies which inhibit specified human polypeptides and pharmaceutical compositions comprising one or more such antibodies.

Claims14

Dependent claims

A method of treating ischemia-reperfusion injury, the method comprising administering to a patient in need thereof a therapeutically effective dose of a double-stranded ribonucleic acid (RNA) compound comprising the structure:

(SEQ ID NO:
140)
5' AGGAGUUCCACAUUCUGGC-Z 3' (antisense strand)
(SEQ ID NO:
139)
3' Z'-UCCUCAAGGUGUAAGACCG 5' (sense strand);
wherein each A, C, G, and U is a ribonucleotide which may be modified or unmodified in its sugar residue and wherein each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond;
and
wherein each of Z and Z′ may be present or absent, but if present is 1 to 5 consecutive nucleotides covalently attached at the 3′ terminus of the strand in which it is present;
or a pharmaceutically acceptable salt of the double-stranded RNA compound.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/592,386Filed 8 Jan 2015 · continuation

Priority

25 Oct 2006

Published

US 2015/0329866 A119 Nov 2015

Granted

20 Sep 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification29 codes

C12N 15/1137
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against enzymes
A61K 31/70
Medicinal preparations containing organic active ingredients: carbohydrates; Sugars; Derivatives thereof
A61P 9/00
Drugs for disorders of the cardiovascular system
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…

Family

Application60/854,503Us provisional application · filed 25 Oct 2006

Application60/930,493Us provisional application · filed 15 May 2007

Application11/978,089Parent of this continuation · filed 25 Oct 2007

US 2015/0329866 A1Pre-grant publication · published 19 Nov 2015

US 2009/0162365 A1Published application

US 9,446,062 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods of treating ischemia-reperfusion injury with siRNAs

Life of this patent

Methods of treating ischemia-reperfusion injury with siRNAs

Life of this patent

Abstract

Claims14